Towards freedom from disease? Episode 1

This webinar will focus on the unmet needs that exist in the management of psoriatic arthritis and on how new data from available or pipeline compounds can help address these needs in clinical practice. We invite rheumatologists and dermatologists from around the world to tune in for the presentations given by the esteemed faculty and to interact with them during the interactive segments of the programme.

We hope you can join us during this live, interactive session. If you are unable to attend the live broadcast, you will be able to watch the on-demand version once it is available.

Learning objectives

After this webinar, participants should be able to:

• Describe how the IL-23 pathway is a target in the treatment of both psoriasis and psoriatic arthritis
• Relate the pathobiology of psoriasis and psoriatic arthritis to the potential efficacy of new treatment options in the current treatment landscape of the disease
• Identify patient groups who can benefit from treatments targeting the IL-23 pathway

Faculty

• Wolf-Henning Boehncke
• Dennis McGonagle
• Georg Schett

Programme (all times in CET)

17:30–17:35 Welcome
Dennis McGonagle

17:35–17:50 IL-23 inhibitors in the skin: the current situation
Wolf-Henning Boehncke

17:50–18:05 Why study IL-23 in the joint?
Georg Schett

18:05–18:15 IL-23 data in PsA
Dennis McGonagle

18:15–18:25 Optimizing management for patients – interactive panel discussion and Q&A
Wolf-Henning Boehncke, Dennis McGonagle and Georg Schett

18:25–18:30 Summary and close
Wolf-Henning Boehncke